NYSE:NKGN NKGen Biotech (NKGN) Stock Price, News & Analysis $0.19 0.00 (0.00%) As of 07/25/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NKGen Biotech Stock (NYSE:NKGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NKGen Biotech alerts:Sign Up Key Stats Today's Range$0.19▼$0.1950-Day Range$0.19▼$0.3852-Week Range$0.10▼$1.29VolumeN/AAverage Volume1.79 million shsMarket Capitalization$8.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California. Read More NKGen Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreNKGN MarketRank™: NKGen Biotech scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NKGen Biotech. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NKGen Biotech is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NKGen Biotech is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.16% of the float of NKGen Biotech has been sold short.Short Interest Ratio / Days to CoverNKGen Biotech has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NKGen Biotech has recently increased by 13.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNKGen Biotech does not currently pay a dividend.Dividend GrowthNKGen Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.16% of the float of NKGen Biotech has been sold short.Short Interest Ratio / Days to CoverNKGen Biotech has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NKGen Biotech has recently increased by 13.98%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.08 News SentimentNKGen Biotech has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NKGen Biotech this week, compared to 1 article on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NKGen Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders10.36% of the stock of NKGen Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.17% of the stock of NKGen Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NKGen Biotech's insider trading history. Receive NKGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address NKGN Stock News HeadlinesNKGen Biotech to Present at the Alzheimer's Association International Conference 2025July 22, 2025 | globenewswire.comNKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative DiseasesJuly 21, 2025 | finance.yahoo.comYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $200 on Your Annual SubscriptionJuly 27 at 2:00 AM | MarketBeat (Ad)NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to JapanJuly 17, 2025 | globenewswire.comNKGen Biotech, Inc.: NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing StandardsJuly 17, 2025 | finanznachrichten.deNKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing StandardsJuly 16, 2025 | globenewswire.comNKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s ...July 12, 2025 | morningstar.comMNKGen Biotech, Inc.: NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting TherapyJuly 11, 2025 | finanznachrichten.deSee More Headlines NKGN Stock Analysis - Frequently Asked Questions How have NKGN shares performed this year? NKGen Biotech's stock was trading at $0.6552 at the beginning of the year. Since then, NKGN shares have decreased by 71.0% and is now trading at $0.19. How do I buy shares of NKGen Biotech? Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NKGen Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI). Company Calendar Today7/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:NKGN Previous SymbolNYSE:NKGN CIK1845459 Webnkgenbiotech.com Phone949-396-6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.94 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-479.36% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.68) per share Price / Book-0.07Miscellaneous Outstanding Shares44,948,000Free Float40,291,000Market Cap$8.54 million OptionableNot Optionable Beta1.26 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NYSE:NKGN) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.